Category: Pharma News

As part of risk-based inspections that were slated to take place in December of last year, pharmaceutical companies across the country were raided: CDSCO

According to senior CDSCO officials involved in the process, the risk-based inspections that the Central Drugs Standard Control Organization (CDSCO) scheduled for December of last year resulted in the cancellation of licences for 18 Indian pharmaceutical companies for producing fake…

To cure vascular and pigmented under-eye dark circles, Entod Beauty London introduces “Eyecirque Advance.”

In order to address pigmented and vascular under-eye dark circles, Entod Beauty London has recently introduced a unique gel serum called “Eyecirque Advance.” A powerful anti-vascular, anti-pigmentation, and anti-aging nanomolecule blend of tranexamic acid, alpha arbutin, glycolic acid, moringa extract,…

Positive findings from the second interim analysis of the phase 2 randomised trial for BX1000 are reported by Baudax Bio.

The second preplanned interim analysis of Baudax Bio, Inc.’s phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery showed promising results. Baudax Bio, Inc. is a pharmaceutical company that specialises in developing novel products for…

Drug Regulator ने शुरू की राष्ट्रव्यापी कार्रवाई, नकली दवाओं के निर्माण के लिए फार्मा कंपनियों का लाइसेंस रद्द

The drug regulator has revoked the licences of several pharmaceutical enterprises operating in about 20 states nationwide due to concerns expressed by numerous public health experts and even certain pharmaceutical manufacturers regarding the prevalence of substandard quality medicines in the…

As the Union government adds new conditions to the NPRD list, patient groups are awaiting clarification on the inclusion of rare diseases.

Patient advocacy groups are awaiting clarification on whether specific conditions will be covered by the National Policy of Rare Disorders (NPRD) 2021. This comes after the Union government recently allowed patients to receive treatment for six rare diseases by including…

In an experimental research using the ROCK inhibitor NRL-1049 to treat cerebral cavernous malformations, Neurelis has started patient dosing.

The Rho kinase (ROCK) inhibitor NRL-1049, a potential treatment for people with cerebral cavernous malformations (CCM), a condition marked by abnormally enlarged capillary cavities in the brain and spinal cord, was dosed in the first two cohorts of the investigational…

Back to top
WhatsApp Join Telegram